Efficacy and Safety of Cerebroprotein Hydrolysate I Combined with Rehabilitation Training in the Treatment of Provisional Intellectual Developmental Disorder in Children.

Purpose: As there are currently limited pharmacologic interventions for provisional intellectual development disorder (PIDD), with treatment mainly relying on rehabilitation training and education, this study aimed to evaluate the efficacy and safety of cerebroprotein hydrolysate I (CH-I) in children with PIDD. Patients and Methods: We conducted a prospective study of 102 children under three years of age who were diagnosed with PIDD in a hospital setting. The control group received standardised rehabilitation training comprising physical therapy, occupational therapy, speech therapy and cognitive development training. In addition to this, the treatment group received a 14-day course of continuous intravenous CH-I infusions, followed by 76 days of oral administration of its derivatives. Neurological function was assessed using the Gesell developmental scales, and brain changes were evaluated using magnetic resonance imaging (MRI) scans. Adverse reactions were closely monitored throughout the study. Changes in various indicators were compared between the two groups at baseline and at 14, 30, 60 and 90 days after treatment. Results: At 90 days of treatment, the treatment group showed greater improvement than the control group in fine motor and adaptive functioning compared to their respective baseline periods, and the difference was statistically significant ( Conclusion: CH-I may help to improve fine motor skills and adaptability in children under three years of age with PIDD, improve rehabilitation efficiency, and have good clinical safety.